Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials
- Mohamed Rahouma(corresponding author),
- Nagla Abdel Karim,
- Massimo Baudo,
- Maha Yahia,
- Mohamed Kamel,
- Ihab Eldessouki
- Cairo University,
- University of Cincinnati,
- Cornell University,
- University of Texas MD Anderson Cancer Center,
- University of Turin
Open access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Background: With antiprogrammed death receptor-1 (anti-PD-L1) therapy, a recent meta-analysis reported higher incidence of cutaneous, endocrine and gastrointestinal complications especially with dual anti-PD-L1 immunotherapy (IMM). Methods: Our primary outcome was assessment of all cardiotoxicity grades in IMM compared with different treatments, thus a systemic review and a meta-analysis on randomized clinical trials (RCTs) were done. Results: We included 11 RCTs with 6574 patients (3234 patients in IMM arm vs 3340 patients in the other arm). Three non-small-cell lung cancer RCTs, seven melanoma RCTs and only one prostatic cancer RCT met the inclusion criteria. There were five RCTs that compared monoimmunotherapy to chemotherapy "(n = 2631 patients)". No difference exists in all cardiotoxicity grades or high-grade cardiotoxicity (p > 0.05). Lung cancer exhibited a higher response rate and lower mortality in IMM. Conclusion: There was no reported statistically significant cardiotoxicity associated with anti-PD/PD-L1 use. Lung cancer subgroups showed better response and survival rates.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 725-735 (11 pages)Journal (Volume, Issue Number)
Immunotherapy (Volume 11, Issue 8)Publication milestones
- Published - 05/15/2019
Publication status
ISSN
1750-743XPublication IDs
- Scopus: 85065989264
- PubMed: 31088241
